Christopher K. Moore

Array ( [id] => 20293817 [patent_doc_number] => 20250319060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-16 [patent_title] => METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 [patent_app_type] => utility [patent_app_number] => 19/037137 [patent_app_country] => US [patent_app_date] => 2025-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19037137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510575 [patent_doc_number] => 20240342261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => Immunogenic Compounds For Cancer Therapy [patent_app_type] => utility [patent_app_number] => 18/751502 [patent_app_country] => US [patent_app_date] => 2024-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447403 [patent_doc_number] => 20240307533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => Reducing side effects of immunotherapy using genetically modified hematopoietic cells [patent_app_type] => utility [patent_app_number] => 18/732517 [patent_app_country] => US [patent_app_date] => 2024-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18732517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19433851 [patent_doc_number] => 20240302349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => METHODS OF ASSESSING OR MONITORING A RESPONSE TO A CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/674099 [patent_app_country] => US [patent_app_date] => 2024-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18674099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691315 [patent_doc_number] => 20250009860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => REPLICATION-DEFICIENT ARENAVIRUS PARTICLES AND TRI-SEGMENTED ARENAVIRUS PARTICLES AS CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 18/658403 [patent_app_country] => US [patent_app_date] => 2024-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18658403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961642 [patent_doc_number] => 12331126 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => OX40-binding polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 18/658421 [patent_app_country] => US [patent_app_date] => 2024-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 18 [patent_no_of_words] => 21083 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18658421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556513 [patent_doc_number] => 20240368305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/628575 [patent_app_country] => US [patent_app_date] => 2024-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526648 [patent_doc_number] => 20240350550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC PROTEINS [patent_app_type] => utility [patent_app_number] => 18/620496 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18620496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19472612 [patent_doc_number] => 12102675 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => MRNA therapeutic compositions [patent_app_type] => utility [patent_app_number] => 18/605049 [patent_app_country] => US [patent_app_date] => 2024-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 52 [patent_no_of_words] => 38782 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18605049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19923000 [patent_doc_number] => 12297271 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => PD-1 single domain antibodies and therapeutic compositions thereof [patent_app_type] => utility [patent_app_number] => 18/589536 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 65138 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462523 [patent_doc_number] => 20240316192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigens [patent_app_type] => utility [patent_app_number] => 18/429213 [patent_app_country] => US [patent_app_date] => 2024-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379405 [patent_doc_number] => 20240269275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigen [patent_app_type] => utility [patent_app_number] => 18/418078 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18418078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142234 [patent_doc_number] => 20240141063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => ANTI-KIT ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/538698 [patent_app_country] => US [patent_app_date] => 2023-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18538698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19156146 [patent_doc_number] => 20240148853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => MRNA THERAPEUTIC COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/505881 [patent_app_country] => US [patent_app_date] => 2023-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18505881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232217 [patent_doc_number] => 20240189408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS [patent_app_type] => utility [patent_app_number] => 18/486678 [patent_app_country] => US [patent_app_date] => 2023-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94549 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281580 [patent_doc_number] => 20240218054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => ANTI-YELLOW FEVER VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE [patent_app_type] => utility [patent_app_number] => 18/485163 [patent_app_country] => US [patent_app_date] => 2023-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18485163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020208 [patent_doc_number] => 20240076379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 [patent_app_type] => utility [patent_app_number] => 18/473002 [patent_app_country] => US [patent_app_date] => 2023-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18473002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19052256 [patent_doc_number] => 20240094225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => DIAGNOSTIC OR PREDICTOR OF RELAPSING REMITTING MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 18/457778 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18457778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18809991 [patent_doc_number] => 20230384326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => TEST METHOD AND TEST KIT FOR ADULT STILL'S DISEASE [patent_app_type] => utility [patent_app_number] => 18/448519 [patent_app_country] => US [patent_app_date] => 2023-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13417 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953503 [patent_doc_number] => 20240041830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => CIRCULATING BIOMARKERS OF RESPONSE TO PD-1/PD-L1 BLOCKADE AND GSK-3 INHIBITION [patent_app_type] => utility [patent_app_number] => 18/365964 [patent_app_country] => US [patent_app_date] => 2023-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 257 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18365964 [rel_patent_id] =>[rel_patent_doc_number] =>)